-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Guide: According to statistics, in the consultation and consultation on hair loss, more than 50% of the proportion is shown as 90.
, did you have hair loss? The problem is not limited to older and middle-aged men, but also to young men, young women and middle-aged women.
perhaps the male gays reading this article at the moment will wonder, do lesbians also have hair loss problems? That's right.
"big wave roll" and "small wave roll" in addition to exude the charm of women, but also from the visual "hair."
young people in this city, no one is easy... The concepts of "drunk today and drunk" and "sleep what sleeps hi" continue to ferment among the modern youth population.
living conditions such as staying up late, making irregular stops, and eating unevenly seem to take it for granted.
, in short, everything starts with sensory enjoyment.
of course, the lights at night are not always a carnival for young people.
there are young people's dreams of blood, the pressure of life, the neon lights staged under the urban crowd of the "struggle" series ... ... But, for whatever reason, "it's always important to get out and mix."
the situation of hair loss is serious According to statistics, in the consultation and consultation on hair loss, more than 50% of the proportion appears to be after 90.
hair loss no longer seems to be just a symbol of the "wisdom" of middle-aged men, but a younger trend... The World Health Organization says that on average, one in six people today has symptoms of hair loss, and the incidence rate is increasing at least 15 percent a year.
more than 90 percent of all hair loss patients in this large population are seborrive hair loss (also known as androgenic hair loss, AGA).
statistics, the number of people with seborrfaced hair loss worldwide is more than 700 million.
China's seborrive hair loss drug market size 2014-2018 Picture: Public information Market space is so large that there is currently no better effective drug for seborrive hair loss.
, very few small molecule drugs for seborrel hair loss have been developed.
only drugs approved by the FDA for hair loss treatment are Minoxidil and Finasteride, both of which are generally effective and have more obvious side effects.
In the view of Dr. Wang Zengquan, founder of Tekoro Bio, even if it is the development of a new generation of Minotics, or a new generation of small molecular drugs that inhibit the mechanism of male hormones, there may still be problems with poor performance and side effects.
In this reason, he led the Tecoro biological research and development team intends to start with the hair growth mechanism, the introduction of a better and safer new generation of hair drugs, really from the 'root' to solve the problem of hair loss patients.
, starting with solving the problem of hair loss, focused on the field of dermatology Tecoro Biology, known as Jiaxing Tekoro Biotech Co., Ltd., was established in March 2014 in Jiaxing City, Zhejiang Province, Xiuzhou National High-tech Zone.
has focused on the development of new drugs for skin-related diseases worldwide, building a global new drug development platform for First-in-Class, which specializes in skin-related diseases.
, Tecoro Bio's first hair-having project has successfully developed drug molecules with significant hair-having efficacy and globally independent intellectual property rights.
the drug molecule has been chinese patents, PCT patents, U.S. and Japanese patents, EU patents are entering the examination stage.
The project has completed trials such as drug effectiveness/pharmacogenics, CMC preparation research and preclinical toxicology evaluation trials, and is currently preparing clinical declaration data, which will be the world's first innovative drug to declare the United States IND and launch clinical Phase I trials in the second half of this year.
In addition to the hair-making project, Tecoro Bio has expanded its dermatology research area, developing new drugs in the fields of dermatitis eczema, psoriasis, spot baldness, nail disease and scarring, and has made good progress.
research and development of modern technology is a long and arduous process, how to protect their research and development results from destruction is particularly important for enterprises.
is well aware of this and spares no effort to protect its intellectual property rights.
june of this year, Tecoro Bio filed a patent application for the invention of the fifth series of small molecule compounds, and is currently working on the sixth and seventh patents.
8-10 patents in this area this year, according to the Company's Tkoro Bio.
the research and development efficiency of the Tetkoro organism is amazing.
, founder of Tetcoro, said Tkoro Bio needs to develop a sustainable competitive advantage in intellectual property rights and increase protection of drug development technologies.
, if there is a strong intellectual property rights in the field of immune and inflammatory skin diseases, multiple adaptations can be laid out in parallel for drug development.
, Tecoro Bio has completed tens of millions of angel round financing and pre-A round financing, is currently in the process of 60 million yuan round A financing.
This round of funding will be used primarily to advance preclinical research and advance phase I clinical studies of dermatitis eczema and psoriasis drug-related projects, with the remainder going to phase II clinical research preparation for hair development projects and the expansion of the research and development team."
TDM-105795, the TDM-105795, a product of Tecoro Bio's first hair project, is currently its fastest-promoting product line.
TDM-105795 is suitable for seborrheic hair loss, the main hair process is to activate hair follicle stem cells, induce dormant hair follicles into the growth period, prolong the growth period, shorten the degenerative period and sleep period, in order to achieve the effect of treating hair loss.
TDM-105795 has the potential for superior efficacy and better safety than its peers.
The results of animal experiments of this project show that TDM-105795 has a fast effect, and the hair growth effect is significant on 3-5 days after the drug use, and the whole hair growth cycle can be completed by 15-18 days, which is much better than that of Minodir.
, the dose of TDM-105795 was also lower, with a minimum effective dose (MED) of 0.001%, with significant hair growth.
At present, the project has completed the drug effect / drug generation and other experiments, CMC preparation research and preclinical toxicology evaluation trials, has begun to prepare for clinical declaration of data, will be the world's first innovative drug in the second half of this year to declare the United States IND and start clinical Phase I trials.
, the market for seborrfaced hair loss treatments is expected to reach $11.8 billion by 2022, an annual growth rate of 7%, according to market research.
drug research and development platform, in-depth layout of dermatitis eczema, psoriasis areas for clinical needs pain points and significant differentiation angle cut is Tekoro bio to ensure its competitive advantage weapon.
has its own research and development platform for inflammatory skin disease drugs.
, the company has developed an in-depth layout for other areas of skin diseases such as dermatitis eczema and psoriasis.
eczema is a major type of perverted reaction associated with chronic, recurrent itching, inflammatory skin diseases, of which specific dermatitis (AD) is a representative disease.
as high as 15%-20% AD incidence among children in China, and there is a rising trend, with more than 20 million child-specific patients in China alone.
incidence of AD in adults is lower, about 1% to 3%.
overall, more than 90% of patients are mild and moderate.
treatment of mild and moderate dermatitis eczema is mainly the use of hormones, calcium neurophosphatase inhibitors, PDE4 inhibitors and other external drugs, side effects are relatively large, the effect is not significant.
, Tkoro Bio launched an early drug development program for psoriasis and dermatitis eczema in 2018, and has successfully discovered several pilot compounds and filed patent applications in bulk.
preclinical effectiveness trials of drug candidate compounds that have been selected by the United States have shown that the drug candidates of Tecoro organisms in this indication have been equivalent to hydrocorrosion.
project has entered the CMC phase of research, is expected to be Q3 in the United States in 2021 to declare the United States IND and start clinical Phase I trials.
estimates that the global dermatitis eczema drug market is worth more than $4 billion.
Psoriasis is a common chronic recurrent inflammatory skin disease characterized by red or sepia papules or plaques, the surface is covered with silvery white scales, mostly occurs in scalp and limb extension, a small number of patients have pustules damage or arthritis symptoms, or the whole body skin redness, dandruff and red skin disease.
statistics, the number of psoriasis patients worldwide exceeds 125 million.
the incidence rate in Europe and the United States is about 2%-3%, the incidence rate in the Asian region is about 0.2%, and the number of patients in China exceeds 6 million.
, psoriasis commonly used external drugs are mainly glucososteroids, vitamin derivatives and vitamin acid preparations, the effect is generally obvious and the side effects are obvious.
recent new batch of Benvimod cream treatment of psoriasis clinical and market performance remains to be seen.
's sales in eight major markets, including the UK, US, France, Germany, Italy, Spain, Japan and India, reached US$6.6 billion in 2014 and are expected to grow to US$13.1 billion in 2024, according to GlobalData.
said the global psoriasis market could well exceed its $21bn market estimate by 2024.
that the market prospects for dermatology drugs are huge.
expected to go public within 2-3 years, cooperation can go further Tekoro in the deep-cultivation technology at the same time, but also actively cooperate with the outside world.
in China, Tkoro Bio has established cooperative relations with CRO enterprises, and is also a partner of Medicinal Mingkangde, Via Bio, Wise Chemistry, Suzhou Sansu, Chengdu Haitang National Security Evaluation Center, etc.
2019, Tecoro Bio partnered with Chesson Labs of the United States to introduce two of the company's products, LiquiCure and Nuva Nail, as sales partners in Chinese mainland.
because Tecoro biological research and development drugs focus on the field of skin diseases, its drugs are mainly through external application of the form of skin administration to play a therapeutic role.
selection of small molecule drug candidates that are most suitable for skin local drug absorption and effective is the core competence of the team's technology.
how to use the best pharmaceutical preparation process, to maximize the efficacy of the drug is also Tecoro bio-follow-up to promote related drugs need to take into account the problem and the opportunity to seek broad cooperation.
, Dr. Wang Zengquan, said that while Tekoro Bio's current focus is on early drug development and clinical research, the follow-up will certainly enter such a phase of industrialization and commercialization.
company welcomes the cooperation and layout of industrialization and commercialization, and is also beginning to cooperate on projects.
asked about the company's plans for the last two years, Dr. Wang said the company's focus is on making the project solid.
is expected to push three drugs into clinical practice between 2021 and 2022.
Referring to the current boom in listings of popular biopharmaceutical companies, Dr Wang told Arterial.com: "The company is now expected to go public in 2022-2023, 2022 or on NASDAQ, or on the Hong Kong Stock Exchange, and does not rule out a listing on the domestic version."
the best time to go public and the best place for the company's long-term development, depending on the clinical progress of the project.
"